1 / 29

A clinical challenge: integrating all agents

A clinical challenge: integrating all agents. Edith A Perez, MD Mayo Clinic Jacksonville, Florida, USA Introduction by Christoph Zielinski University Hospital Vienna, Vienna, Austria. Case history. 49-year-old woman: 1.4cm lesion in the left breast Lumpectomy and axillary lymphadenectomy

bevan
Télécharger la présentation

A clinical challenge: integrating all agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A clinical challenge: integrating all agents Edith A Perez, MD Mayo ClinicJacksonville, Florida, USA Introduction byChristoph ZielinskiUniversity Hospital Vienna, Vienna, Austria

  2. Case history • 49-year-old woman: 1.4cm lesion in the left breast • Lumpectomy and axillary lymphadenectomy • Poorly differentiated, infiltrating ductal carcinoma • grade 3 • ER/PR negative • HER2 IHC 1+ (negative) • Three positive axillary nodes of 29 examined • Social history: three young children

  3. Clinical course • Adjuvant therapy with dose-dense doxorubicin/cyclophosphamide followed by paclitaxel • Relapsed with multiple metastases in liver, lung and bone within 1.5 years • Abdominal and low level bone pain • several small spinal spots • several bilateral rib lesions • back pain high thorax

  4. Anthracyclines or single-agent taxanes not optimal for this patient • Anthracyclines • frequently used in adjuvant • re-use in metastatic not always possible, or justified, due to • cumulative cardiotoxicity • Taxanes • have been gold standard • combination preferable to single-agent • Xeloda added to Taxotere improves survival

  5. Other single-agent options • Vinorelbine • varying response rates; lack of randomized data • Gemcitabine • varying response rates; lack of randomized data • Xeloda • comparable efficacy versus CMF or paclitaxel • favorable safety profile and convenient

  6. Combination anthracycline/taxane no better than sequence • ECOG study E1193 in first-line MBC compared • doxorubicin plus paclitaxel (AP) • doxorubicin paclitaxel • paclitaxel doxorubicin • AP versus sequential single agents • better disease control • better time to progression • no change in survival or QoL Sledge G et al. J Clin Oncol 2003;21:588–92

  7. Combination XT superior survival versus T X Beslija1 O’Shaughnessy2 • All endpoints statistically significant difference 1Beslija S et al. Eur J Cancer Suppl 2005;3:118 (Abst 407) 2O’Shaughnessy J et al. J Clin Oncol 2002;20:2812–23

  8. Avastin plus paclitaxel significantly improves efficacy versus paclitaxel alone • First-line Avastin plus paclitaxel (n=350) versus paclitaxel alone (n=332) • response rate: 29.9 vs 13.8%, p<0.0001 • 5-month PFS improvement • 11.4 vs 6.11 months • HR=0.51; p<0.0001 Miller KD et al. Breast Cancer Res Treat 2005;94:S6 (Abst 3)

  9. Non-overlapping toxicity when Avastin is added to paclitaxel Miller KD et al. Breast Cancer Res Treat 2005;94(Suppl. 1):S6 (Abst 3)

  10. Recent evidence for Avastin plus docetaxel • Phase II trial (first-/second-line MBC) • Analysis of efficacy in first 13 patients • 7 partial responses (54%) • 4 stable disease (31%) • Acceptable toxicity • few grade 3/4 adverse events attributable to Avastin in therapeutic regimen Ramaswamy B et al. Breast Cancer Res Treat 2003;81:S50 (Abst 224)

  11. Phase III Xeloda versus Xeloda/Avastinin A/T-pretreated MBC • 3-weekly regimen • Xeloda 1250mg/m2 twice daily, days 1–14 • Avastin 15mg/kg, day 1 A/T = anthracycline/taxane Miller K et al. J Clin Oncol 2005;23:792–9

  12. Xeloda/Avastin: minimal added toxicity Miller K et al. J Clin Oncol 2005;23:792–9

  13. Progression of angiogenic activity in human breast tumors Tumor growth VEGF VEGF bFGF TGF-1 VEGF bFGF TGF-1 PlGF VEGF bFGF TGF-1 PlGF PD-ECGF VEGF bFGF TGF-1 PlGF PD-ECGF Pleiotrophin VEGF = vascular endothelial growth factorbFGF = basic fibroblast growth factorTGF-1 = transforming growth factor beta-1PlGF = placental growth factorPD-ECGF = platelet-derived endothelial cell growth factor Relf M et al. Cancer Res 1997;57:963–9

  14. Considerations for the addition of Avastin to chemotherapy in this patient • Anti-angiogenic therapy has biological and clinical merits in first line • non-overlapping toxicities with chemotherapy • Addition of Xeloda to Taxotere (XT) extends survival • Adding Avastin to paclitaxel significantly improves response and PFS • Combination of Avastin with XT may furtherimprove outcomes

  15. Antitumor activity of Xelodacombined with Avastin Mean tumor volume (mm3) 1000 800 600 400 200 0 KPL4 ER– xenograft Control X ½ MTD X MTD A A + X ½ MTD A + X MTD 14 16 18 20 22 24 26 28 30 32 Days post-tumor cell implant

  16. Recommendation for the treatment of this patient • Consider the patient’s characteristics • relatively young: only 49 years at first diagnosis; 51 years at relapse to metastatic disease • adjuvant anthracyclines/paclitaxel • reasonably fit (ECOG PS = 1) • fast-progressing, aggressive disease • Clinical trial with Xeloda/Taxotere/Avastin (XTA)is an attractive option for this patient • XTA trial (NCCTG 0432; PI Edith Perez) is ongoing

  17. 1 8 15 21 Days 1–14 Rest NCCTG 0432: phase II trial of first-line Xeloda/Taxotere/Avastin (n=46) • Some other studies use X900T60 Day Taxotere75mg/m2 Avastin 15mg/kg Repeat cycle at day 22 Xeloda825mg/m2twice daily (oral) Unpublished data courtesy of Dr E Perez

  18. N0432: baseline characteristics (n=46) Unpublished data courtesy of Dr E Perez

  19. XTA: low incidence of non-hematologic grade 3/4 adverse events Patients (%) 80 70 60 50 40 30 20 10 0 HFS Rash Fatigue Nausea Diarrhea Vomiting Stomatitis Febrileneutropenia Neuromotor Leucopenia Neutropenia Unpublished data courtesy of Dr E Perez

  20. Why choose oral Bondronat? • Convenience of oral dosing instead of i.v. • Oral Bondronat has comparable bone marker efficacy to i.v. zoledronic acid • Oral Bondronat controls and maintains bone pain significantly below baseline levels

  21. Clinical course continued • Chemotherapy interrupted (Avastin continued), diarrhea rapidly resolved • Cycle 3 XT restarted at same doses, as planned • patient education important • prescription for loperamide • Symptoms (bone pain) fully resolved by endof cycle 3

  22. Clinical course continued • Patient maintained on Xeloda/Avastin only • Bondronat continued • After 18 months • partial response maintained • symptom free • occasional grade 1 hand-foot syndrome managed with treatment interruption

  23. Therapy with Xeloda and Avastin should be continued until disease progression • Oral Xeloda • effective with demonstrated use for up to 5 years • favorable safety profile, minimal myelosuppression and alopecia • common side effects easily managed • Avastin • use until disease progression strongly supported by mechanism of action • demonstrates benefit when used until progression in clinical trials • is well tolerated; most common side effects are mild and easily manageable

  24. Addressing a clinical challenge in MBC • Appropriate doses of Xeloda and taxane allow patients to • reap the benefits of this active combination • receive a well-tolerated treatment • Adding Avastin to XT should further improve outcomes, with minimal added toxicity • Bondronat offers skeletal related events efficacy and outstanding bone pain relief without renal safety complications

More Related